The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Abstract
BACKGROUND: Echinocandins are recommended for Candia glabrata candidemia. Mutations in the FKS1 and FKS2 genes are associated with echinocandin resistance. Few studies have assessed risk factors for FKS mutant isolates and outcomes in patients receiving micafungin treatment. METHODS: Patients with C. glabrata bloodstream infection admitted to a large, tertiary care hospital between 2009 and 2012 were included in this study. For each isolate, FKS1 and FKS2 genes were sequenced to identify mutations. Risk factors for FKS mutations and treatment outcomes in patients receiving an echinocandin were assessed using multivariate logistic regression. RESULTS: Seventy-two patients were included in the study of which 13 (18%) had an FKS mutant isolate. The only significant predictor for FKS mutations was prior echinocandin exposure (odds ratio [OR], 19.9; 95% confidence interval [CI], 4.7-84.7; P ≤ .01). Treatment failure occurred in 17 (30%) of 57 patients who received an echinocandin and was more common in patients with FKS mutants (6 of 10; 60%) compared with non-FKS mutants (11 of 47; 23%). Underlying gastrointestinal disorder (OR, 4.7; 95% CI, 1.1-20.9; P = .04) and prior echinocandin exposure (OR, 8.3; 95% CI, 1.7-40.4; P ≤ .01) were independent predictors of echinocandin treatment failure. Treatment response and echinocandin minimum inhibitory concentrations varied among specific FKS mutations. CONCLUSIONS: FKS mutations were identified in 18% of 72 patients with C. glabrata candidemia. Common risk factors for FKS mutant isolates included previous echinocandin exposure, which also influenced response rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274
Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01079-10 · Cited by 238
Espinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216 · cited 1×
“With recent concerns over variability in caspofungin MICs obtained by CLSI BMD as well as limited data regarding the performance of echinocandin MICs obtained by commercial testing methods in predicting treatment outcomes, clinicians need to be aware of the testing methods used by their clinical microbiology laborator…”
Zimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136 · cited 1×
“Hot spots 1and 2 of FKS1 and FKS2 were amplified by polymerase chain reaction (PCR) as previously described [9].”
Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06369-11 · Cited by 117 · cited 2×
“glabrata (FKS1 S629P, F625S, D632G or E and FKS2 S663P and F659V or Y) exhibit highly elevated echinocandin MICs and reduced glucan synthase enzyme sensitivity and are unresponsive to even high doses of echinocandins in murine models [6, 14].”
Beyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109 · cited 2×
“This is consistent with both in vitro data as well as numerous reports that implicate these specific FKS mutations in patients failing echinocandin treatment [4].”
Cited by
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Resistance of Candida to azoles and echinocandins worldwide
Pristov, K. E., & Ghannoum, M. A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.03.028 · Cited by 706
Antifungal resistance: current trends and future strategies to combat
Wiederhold, N. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s124918 · Cited by 468
Mechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
Vallabhaneni, S., Cleveland, A. A., Farley, M. M., Harrison, L. H., Schaffner, W., Beldavs, Z. G., Derado, G., Pham, C. D., Lockhart, S. R., & Smith, R. M. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv163 · Cited by 187
Emerging multidrug-resistant Candida species
Colombo, A. L., Júnior, J. N. D. A., & Guinea, J. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000411 · Cited by 177
Drug-Resistant Candida glabrata Infection in Cancer Patients
Farmakiotis, D., Tarrand, J. J., & Kontoyiannis, D. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2011.140685 · Cited by 152
The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145
The antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149
Antifungal Resistance: a Concerning Trend for the Present and Future
Hendrickson, J. A., Hu, C., Aitken, S. L., & Beyda, N. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0702-9 · Cited by 139
Self-citationPfaller, M. A., Rhomberg, P. R., Messer, S. A., Jones, R. N., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.04.008 · Cited by 127
Abdominal candidiasis is a hidden reservoir of echinocandin resistance
Shields, R. K., Nguyen, M. H., Press, E. G., & Clancy, C. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04134-14 · Cited by 118
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84
CD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81
Rogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Dellière, S., Healey, K., Gits-Muselli, M., Carrara, B., Barbaro, A., Guigue, N., Lecefel, C., Touratier, S., Desnos-Ollivier, M., Perlin, D. S., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02038 · Cited by 75
Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland
Coste, A. T., Kritikos, A., Li, J., Khanna, N., Goldenberger, D., Garzoni, C., Zehnder, C., Boggian, K., Neofytos, D., Riat, A., et al. (2020) · Infection · doi:10.1007/s15010-020-01475-8 · Cited by 69
Rapid Detection of FKS -Associated Echinocandin Resistance in Candida glabrata
Zhao, Y., Nagasaki, Y., Kordalewska, M., Press, E. G., Shields, R. K., Nguyen, M. H., Clancy, C. J., & Perlin, D. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01574-16 · Cited by 61
Sharma, D., Paul, R. A., Rudramurthy, S. M., Kashyap, N., Bhattacharya, S., Soman, R., Shankarnarayan, S. A., Chavan, D., Singh, S., Das, P., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01652-21 · Cited by 60
Gamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642358 · Cited by 58
Singh, A., Healey, K. R., Yadav, P., Upadhyaya, G., Sachdeva, N., Sarma, S., Kumar, A., Tarai, B., Perlin, D. S., & Chowdhary, A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00195-18 · Cited by 56
Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection
Shields, R. K., Nguyen, M. H., Press, E. G., Cumbie, R., Driscoll, E., Pasculle, A. W., & Clancy, C. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01973-15 · Cited by 55
Khatib, R., Johnson, L. B., Fakih, M. G., Riederer, K., & Briski, L. (2016) · Mycoses · doi:10.1111/myc.12531 · Cited by 48
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Fukuda, Y., Mitsuyama, J., & Patterson, T. F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv398 · Cited by 48
We can do better: a fresh look at echinocandin dosing
Bader, J. C., Bhavnani, S. M., Andes, D. R., & Ambrose, P. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx448 · Cited by 46
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Pizzini, J., Catano, G., & Patterson, T. F. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx422 · Cited by 43
Genetic Basis of Azole and Echinocandin Resistance in Clinical Candida glabrata in Japan
Khalifa, H. O., Arai, T., Majima, H., Watanabe, A., & Kamei, K. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00783-20 · Cited by 42
Bassetti, M., Vena, A., Bouza, E., Peghin, M., Muñoz, P., Righi, E., Pea, F., Lackner, M., & Lass-Flörl, C. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.02.017 · Cited by 40
Biswas, C., Chen, S. C.-A., Halliday, C., Kennedy, K., Playford, E. G., Marriott, D. J., Slavin, M. A., Sorrell, T. C., & Sintchenko, V. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.03.014 · Cited by 36
“Echinocandin resistance involves mutations in the FKS1 and FKS2 genes 76 which encode β-1,3-D-glucan synthase, and can predict treatment f ailures [3-5].”
BackgroundMcCarty, T. P., Lockhart, S. R., Moser, S. A., Whiddon, J., Zurko, J., Pham, C. D., & Pappas, P. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky059 · Cited by 21
Ksiezopolska, E., Schikora-Tamarit, M. À., Carlos Nunez-Rodriguez, J., & Gabaldón, T. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1416509 · Cited by 15
Lin, W., Peng, Y., Xiang, B., Fang, J., Ye, J., & Guo, P. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04275-y · Cited by 3
Metadata
- Authors
- Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-05-30
- Volume
- 59
- Issue
- 6
- Pages
- 819-825
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2130198427
- Cited by
- 174
- References
- 10
- FWCI
- 15.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.